World Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Report 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview
  3. Therapeutics Development
  4. Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
  5. Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis
  6. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies
  7. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes
  8. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies
  13. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes
  14. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
  • Altor BioScience Corporation
  • Aprea AB
  • arGEN-X BV
  • Ariad Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Baxalta Incorporated
  • BioSight Ltd.
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Deciphera Pharmaceuticals, LLC
  • Eisai Co., Ltd.
  • EpiZyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gamida Cell Ltd.
  • GlycoMimetics, Inc.
  • HEC Pharm Co., Ltd.
  • Hybrigenics S.A.
  • Ilyang Pharmaceutical Co., Ltd.
  • Incyte Corporation
  • Lixte Biotechnology Holdings, Inc.
  • Mirna Therapeutics, Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Oribase Pharma
  • Panther Biotechnology, Inc.
  • Pfizer Inc.
  • Sanofi
  • Sun Pharma Advanced Research Company Ltd.
  • Takeda Pharmaceutical Company Limited
  • Targazyme, Inc.
  • Teva Pharmaceutical Industries Ltd.

For more information visit http://www.researchandmarkets.com/research/9qjhmc/chronic.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Leukemia Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Leukemia Drugs